Pacira BioSciences (PCRX) Gains from Investment Securities (2019 - 2026)

Pacira BioSciences' Gains from Investment Securities history runs 8 years deep, the most recent figure standing at -$2.3 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities rose 15.67% year-over-year to -$2.3 million; the TTM figure through Mar 2026 stood at -$1.8 million (up 46.97% YoY), while the FY2025 annual figure was -$2.2 million, up 51.2% from the prior year.
• Gains from Investment Securities for Q1 2026 stood at -$2.3 million, down from $232000.0 in the prior quarter.
• The five-year high for Gains from Investment Securities was $12.5 million in Q2 2022, with the low at -$18.3 million in Q2 2023.
• The 5-year median for Gains from Investment Securities is $232000.0 (2025), against an average of -$385058.8.
• Peak annual rise in Gains from Investment Securities reached 12400.0% in 2022, while the deepest fall reached 606.83% in 2022.
• Pacira BioSciences' Gains from Investment Securities stood at -$6.1 million in 2022, then soared by 106.95% to $423000.0 in 2023, then surged by 156.26% to $1.1 million in 2024, then plunged by 78.6% to $232000.0 in 2025, then sank by 1081.47% to -$2.3 million in 2026.
• Business Quant data shows PCRX's Gains from Investment Securities at -$2.3 million in Q1 2026, $232000.0 in Q4 2025, and $625000.0 in Q3 2025.